Niveles séricos de IGF-1 e IGFBP-3 en pacientes con esófago de Barrett y adenocarcinoma de esófago. Estudio longitudinal

Sharma, 2006, Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus, Clin Gastroenterol Hepatol., 4, 566, 10.1016/j.cgh.2006.03.001 Singh, 2014, Incidence of esophageal adenocarcinoma in Barrett's esophagus with low grade dysplasia: A systematic review and meta-analysis, Gastrointest Endosc., 79, 897, 10.1016/j.gie.2014.01.009 Reid, 2000, Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high risk patient subsets, Am J Gastroenterol., 95, 1669 Shaheen, 2022, Diagnosis and management of Barrett's esophagus: An updated ACG Guideline, Am J Gastroenterol., 117, 559, 10.14309/ajg.0000000000001680 Weusten, 2017, Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement, Endoscopy., 49, 191, 10.1055/s-0042-122140 Nguyen, 2021, Prevalence of Barrett's esophagus and performance of societal screening guidelines in an unreferred primary care population of U.S. veterans, Gastrointest Endosc., 93, 409, 10.1016/j.gie.2020.06.032 Rodríguez-D’Jesús, 2014, Prevalencia y características epidemiológicas del EB en la provincia de Barcelona, Gastroenterol Hepatol., 37, 397, 10.1016/j.gastrohep.2014.01.013 Bosetti, 2008, Trends in esophageal cancer incidence and mortality in Europe, Int J Cancer., 122, 1118, 10.1002/ijc.23232 Jemal, 2010, Global patterns of cancer incidence and mortality rates and trends, Cancer Epidemiol Biomarkers Prev., 1, 1893, 10.1158/1055-9965.EPI-10-0437 Calle, 2004, Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms, Nat Rev Cancer., 4, 579, 10.1038/nrc1408 Chow, 1998, Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia, J. Natl Cancer Inst., 90, 150, 10.1093/jnci/90.2.150 Kaaks, 2003, Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls, Eur J Cancer Prev., 12, 309, 10.1097/00008469-200308000-00011 Renehan, 2006, Obesity and cancer risk: The role of the insulin-IGF axis, Trends Endocrinol Metab., 17, 328, 10.1016/j.tem.2006.08.006 Palmqvist, 2003, Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: A prospective study in Northern Sweden, Int J Cancer., 107, 89, 10.1002/ijc.11362 Liu, 2002, Autocrine stimulation by insulin like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells, J Biomed Sci., 9, 665, 10.1007/BF02254995 Renehan, 2004, Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis, Lancet., 363, 1346, 10.1016/S0140-6736(04)16044-3 Greer, 2012, Association of insulin and insulin-like growth factors with Barrett's oesophagus, Gut., 61, 665, 10.1136/gutjnl-2011-300641 Siahpush, 2007, Longitudinal study of insulin-like growth factor, insulin-like growth factor biding protein-3, and their polymorphisms: Risk of neoplastic progression in Barretts’ esophagus, Cancer Epidemiol Biomarkers Prev., 16, 2387, 10.1158/1055-9965.EPI-06-0986 Xie, 2020, Circulating levels of inflammatory and metabolic biomarkers and risk of esophageal adenocarcinoma and Barrett esophagus: Systematic review and meta-analysis, Cancer Epidemiol Biomarkers Prev., 29, 2109, 10.1158/1055-9965.EPI-20-0572 Doyle, 2012, IGF-1 and its receptor in esophageal cancer: Association with adenocarcinoma and visceral obesity, Am J Gastroenterol., 107, 196, 10.1038/ajg.2011.417 Greer, 2013, Insulin/insulin-like growth factor-1 pathway in Barrett's carcinogenesis, Clin Transl Gastroenterol., 4, e31, 10.1038/ctg.2013.2 Friedrich, 2014, Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays, J Clin Endocrinol Metab., 99, 1675, 10.1210/jc.2013-3060 Dighe, 2021, Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma, Carcinogenesis., 42, 369, 10.1093/carcin/bgaa132 Iravani, 2003, Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia, Human pathology., 34, 975, 10.1053/S0046-8177(03)00354-X Bhat, 2011, Risk of malignant progression in Barrett's esophagus patients: Results from a large population-based study, J Natl Cancer Inst., 103, 1049, 10.1093/jnci/djr203 Wang, 2008, The value of traditional upper endoscopy as a diagnostic test for Barrett's esophagus, Gastrointest Endosc., 68, 859, 10.1016/j.gie.2008.02.064 Rodríguez-D’Jesús, 2012, Usefulness of endoscopic biopsy in Barrett's esophagus, Med Clin (Barc)., 139, 103, 10.1016/j.medcli.2011.05.032 Janmaat, 2017, Use of immunohistochemical biomarkers as independent predictor of neoplastic progression in Barrett's oesophagus surveillance: A systematic review and metaanalysis, PLoS One., 12, e0186305, 10.1371/journal.pone.0186305 Fontana, 2007, Aging, adiposity, and calorie restriction, JAMA., 297, 987, 10.1001/jama.297.9.986 Fontana, 2008, Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans, Aging Cell., 7, 681, 10.1111/j.1474-9726.2008.00417.x